Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy

9 juillet 2026 mis à jour par: Mariam ibrahim, Assiut University

Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy: Randomized Clinical Control Trial

Chronic insertional Achilles tendinopathy is a common overuse condition that can be slow to improve with traditional loading-based rehab (e.g., eccentric loading, activity modification, graded return to function). Outcomes are often variable, and persistent symptoms can limit how much load patients can tolerate early in rehab.

This outpatient randomized controlled trial will compare standard-of-care rehabilitation alone versus standard-of-care rehabilitation plus blood flow restriction (BFR) training in adults with chronic insertional Achilles tendinopathy. BFR uses an external cuff to partially restrict blood flow during low-load resistance exercise, aiming to produce strength and hypertrophy adaptations with less mechanical stress than high-load training. Evidence supporting BFR's physiologic effects and safety in musculoskeletal rehab is summarized in clinical research literature.

Participants will be randomized (stratified by baseline activity level and symptom severity) to receive the same rehab program, with the experimental group performing strengthening with BFR using Smart Tools Plus cuffs applied at the proximal thigh and set to 40-80% limb occlusion pressure. The primary outcome will be the VISA-A score (a validated measure of Achilles tendinopathy severity), with secondary outcomes including pain ratings, functional performance tests (e.g., single-leg heel raise endurance, hopping/time-to fatigue), and calf strength via handheld dynamometry.

Aperçu de l'étude

Description détaillée

Chronic insertional Achilles tendinopathy is an overuse condition with prolonged recovery, where outcomes after traditional loading programs can be variable. Your protocol builds on standard rehabilitation principles (progressive loading, symptom-guided activity modification, and graded return to function) while testing whether blood flow restriction (BFR) can improve rehabilitation efficiency by enabling meaningful neuromuscular adaptation at lower external loads. This rationale aligns with emerging mechanistic and clinical evidence that low-load BFR can drive clinically relevant adaptations while reducing mechanical stress on painful tissues.

This study is designed as a two-arm randomized controlled trial conducted in an outpatient rehabilitation setting, comparing standard-of-care rehabilitation alone versus standard-of-care rehabilitation augmented with BFR. The overarching hypothesis is that adding BFR to a structured rehabilitation pathway will yield superior improvements in pain-related disability and function (tracked with validated clinical instruments) and will translate into better performance on functional tasks commonly affected in Achilles tendinopathy (e.g., endurance and hopping tolerance).

To ensure diagnostic precision and a clinically homogeneous sample, the protocol specifies confirmation of chronic insertional Achilles tendinopathy using a combination of symptom chronicity and exam/imaging features, including localized tenderness near the calcaneal insertion, functional provocation testing, and imaging evidence of structural tendon change (ultrasound or MRI). These steps are intended to reduce misclassification and improve interpretability of treatment effects in a condition with multiple pain generators around the posterior heel.

Randomization is structured to enhance baseline balance on variables that can meaningfully influence rehabilitation response. Specifically, allocation is stratified by baseline activity level (Cincinnati Sports Activity Scale) and by baseline clinical severity using a VISA-A threshold (<50 vs ≥50). The target sample size is 40 participants (20 per group), selected to detect a clinically meaningful improvement on the VISA-A (minimal clinically important difference of 10 points) with 90% power and α=0.05, while incorporating an allowance for attrition. The analysis plan is aligned with CONSORT expectations for rehabilitation trials and anticipates covariate-adjusted mixed modeling to evaluate group-by-time effects.

Intervention delivery follows a pragmatic rehabilitation model. The standard-care arm uses established physical therapy approaches-progressive loading (including eccentric-focused strategies), education on activity modification, and a staged return-to-function progression-implemented and advanced based on symptoms and functional tolerance. In the BFR-augmented arm, the same rehabilitation exercises are performed while applying BFR using Smart Tools Plus (LLC, USA) with limb sleeves and cuffs placed proximally on the thigh. Limb occlusion pressure (LOP) is set individually immediately prior to exercise, and the protocol applies 40-80% of LOP during the exercise sets. Participants are monitored throughout for adverse signs/symptoms, consistent with published evidence that BFR-when appropriately screened, dosed, and supervised-has an acceptable safety profile in musculoskeletal rehabilitation populations.

Outcomes are captured longitudinally across baseline and follow-up timepoints and include a patient-reported measure of Achilles tendinopathy severity (VISA-A) and functional performance metrics (e.g., single-leg heel raise endurance, hopping tolerance/time to fatigue), alongside quantification of plantarflexor/calf strength using handheld dynamometry. The VISA-A is a widely used index with published reliability and construct validity for grading clinical severity in Achilles tendinopathy research.

Data will be evaluated using repeated-measures modeling to compare within-group change over time and between-group differences in trajectories, with covariate adjustment consistent with the stratification variables and planned mixed-model approach. Results will be reported at the group level and interpreted in relation to clinically meaningful change thresholds, with the goal of informing whether BFR is a practical and scalable adjunct to standard rehabilitation for chronic insertional Achilles tendinopathy-especially for patients who cannot tolerate higher external loads early in the rehabilitation process.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Asyut, Egypte
        • Faculty of medicine, Assiut university

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Age 18-65 years
  • Chronic insertional Achilles tendinopathy (symptoms >3 months but <3 years)
  • VISA-A score <80
  • Confirmed diagnosis via:
  • Palpation pain within 2 cm of calcaneal insertion
  • Positive single leg-hop test
  • Ultrasound or MRI evidence of structural tendon changes (hypoechoic areas, thickening, or Doppler flow)
  • No prior BFR training as part of rehab within the last 3 months

Exclusion Criteria:

  • Inability to give informed consent
  • Uncontrolled blood pressure (>160/100 mmHg)
  • Uncontrolled diabetes
  • Familial hypercholesterolemia
  • History of deep vein thrombosis
  • History of blood clots
  • Hypercoagulable states
  • Cancer
  • Active infection
  • History of sickle cell anemia
  • Peripheral vascular disease
  • Morbid obesity (BMI >40)
  • End-stage renal disease requiring dialysis
  • Alcohol use disorder / alcohol abuse
  • Claustrophobia
  • Pregnant woman
  • Inability to follow study protocol (e.g., cannot attend visits or comprehend instructions)
  • Psychiatric illness preventing comprehension or interfering with follow up
  • Lymphadenectomy
  • Any clinical finding that places the patient at health risk, impacts the study, or affects completion
  • History of Achilles tendon rupture or surgery
  • Concurrent midportion Achilles tendinopathy or other ankle pathology (e.g., arthritis)
  • Recent treatments within the past 3 months: physiotherapy, local injections, shockwave therapy, orthotic use

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Standard Rehabilitation
Participants receive standard-of-care rehabilitation for chronic insertional Achilles tendinopathy, including eccentric loading, activity modification, and gradual return to function
Participants complete a standardized outpatient rehabilitation program for chronic insertional Achilles tendinopathy. Standard care includes progressive tendon/calf loading using an eccentric-loading emphasis, education and symptom-guided activity modification, and a graded return-to-function progression. The program is delivered under physical therapy supervision using standard exercise tools, with progression based on participant tolerance and clinical response.
Expérimental: Standard Rehabilitation + Blood Flow Restriction (BFR)
Participants receive the same standard-of-care rehabilitation plus blood flow restriction (BFR) training applied during exercise sets using Smart Tools Plus (LLC, USA) cuffs placed on the proximal thigh with a protective sleeve. Limb occlusion pressure (LOP) is set individually at 40-80% immediately before exercise and applied during the entire exercise set.
Participants complete a standardized outpatient rehabilitation program for chronic insertional Achilles tendinopathy. Standard care includes progressive tendon/calf loading using an eccentric-loading emphasis, education and symptom-guided activity modification, and a graded return-to-function progression. The program is delivered under physical therapy supervision using standard exercise tools, with progression based on participant tolerance and clinical response.
Blood flow restriction (BFR) is applied during low-load resistance exercise using Smart Tools Plus cuffs and limb sleeves. The sleeve is used to protect the skin/soft tissue beneath the cuff, and the cuff is placed around the proximal thigh (right and left as applicable). Individual limb occlusion pressure (LOP) is determined immediately prior to exercise; cuff pressure is set to 40%-80% of LOP and maintained during the entire exercise set. Participants are monitored during BFR application for adverse signs/symptoms (e.g., excessive pain, numbness/paresthesia, abnormal discoloration), and BFR is stopped if safety concerns arise.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
VISA-A (Victorian Institute of Sport Assessment-Achilles) Score
Délai: Baseline (pre-intervention) and Week 8 (end of intervention period)
Description: Patient-reported outcome assessing Achilles tendinopathy severity; total score ranges 0-100 with higher scores indicating fewer symptoms/better function. This tool is validated for Achilles tendinopathy and commonly used in research/clinical settings.
Baseline (pre-intervention) and Week 8 (end of intervention period)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Pain Rating (Numeric Pain Rating Scale or Visual Analog Scale)
Délai: Baseline (pre-intervention) and Week 8 (end of intervention period)
Self-reported pain intensity (e.g., NPRS 0-10 or VAS), where higher scores indicate worse pain.
Baseline (pre-intervention) and Week 8 (end of intervention period)
Single-Leg Heel Raise Endurance Test
Délai: Baseline (pre-intervention) and Week 8 (end of intervention period)
Functional performance/endurance measure recorded as repetitions to fatigue (or a pre-specified stopping criterion such as pain limit/technique failure).
Baseline (pre-intervention) and Week 8 (end of intervention period)
Hopping Test (or Time-to-Fatigue Hopping Test)
Délai: Baseline (pre-intervention) and Week 8 (end of intervention period)
Functional performance test recorded as time to fatigue and/or maximum hops completed using a standardized protocol.
Baseline (pre-intervention) and Week 8 (end of intervention period)
Calf Muscle Strength (Handheld Dynamometry)
Délai: Baseline (pre-intervention) and Week 8 (end of intervention period)
Peak force (or average peak across trials) measured with a handheld dynamometer using a standardized position and lever arm; reported in Newtons (N) or kilograms-force (kgf), depending on device settings.
Baseline (pre-intervention) and Week 8 (end of intervention period)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 août 2025

Achèvement primaire (Estimé)

30 juin 2026

Achèvement de l'étude (Estimé)

30 septembre 2026

Dates d'inscription aux études

Première soumission

8 février 2026

Première soumission répondant aux critères de contrôle qualité

9 juillet 2026

Première publication (Réel)

13 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 juillet 2026

Dernière vérification

1 février 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 04-2025-300683

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner